Microbiome in Allogeneic Hematopoietic Cell Transplantation & Immunotherapy

Jonathan U. Peled
Memorial Sloan Kettering Cancer Center, United States

Allogeneic hematopoietic cell transplantation (allo-HCT) offers curative potential for hematologic malignancies, yet complications including graft-versus-host disease (GVHD), infections, and relapse drive substantial mortality. The gut microbiota is one profoundly perturbed during therapy, and we hypothesis that it is a regulator of these outcomes. This presentation integrates multi-center clinical data and mechanistic mouse experiments to study how patterns of microbiota disruption and exposures such as antibiotics predict or even modulate clinical outcomes such as mortality, bloodstream infection, and GVHD.